The panel will decide whether to recommend the Moderna COVID-19 booster shot on Thursday. The Johnson & Johnson vaccine will be discussed on Friday.
Washington — The US Food and Drug Administration Advisory Board will meet the first of two meetings this Thursday to discuss whether to recommend Moderna and Johnson & Johnson boosters. COVID-19 (New Coronavirus Infection) vaccination, And whether it is safe to get a booster shot of a different brand than the first vaccine.
Currently, the Pfizer-BioNTech vaccine is the only vaccine in favor of the FDA, but Pfizer Shot boosters are still Americans over the age of 65, Americans with underlying health, or working. Only approved by certain Americans, such as front-line workers who are at an increased risk of being infected with COVID.
Both the Moderna and Johnson & Johnson vaccines are currently approved by the FDA for use in people over the age of 18, while the Pfizer vaccine is approved for Americans over the age of 12.
At the table on Thursday, the Moderna shot is the first. Moderna is asking the FDA to approve booster shots six months after the second dose, similar to Pfizer’s request. Johnson & Johnson Boosters will be discussed on Friday. They requested booster approval two months after the single-dose vaccine.
This week’s meeting is the first step in the approval process. Based on the advisory board’s recommendations, the FDA will decide whether to approve the booster. The Centers for Disease Control and Prevention then has the final say.
The FDA Panel assisted Pfizer boosters for specific groups September 17.. Five days later, the FDA approved the shot, and on September 24, CDC director Rochelle Walensky signed off.
Another interesting debate expected during the Friday meeting is whether it is safe and effective for people to get booster shots of brands different from the original vaccine dose.
NS Preliminary survey earlier this week Researchers at the National Institute of Infectious Diseases have shown that mixing and matching boosters with the initial vaccine dose may be even more beneficial to those who have taken Johnson & Johnson shots. .. The results showed that people who received the first J & J vaccine showed a higher immune response with different brand boosters than with additional Johnson & Johnson shots.
“It is important to evaluate information about the use of booster doses in different populations, as the available data reveal that protection against symptomatic COVID-19 in certain populations begins to diminish over time.” Said FDA’s Peter Marks in a press release.
Later this month, the same FDA Advisory Board will meet to discuss approval of the Pfizer vaccine for children ages 5-11.
FDA Advisory Board discusses Moderna, J & J COVID boosters
Source link FDA Advisory Board discusses Moderna, J & J COVID boosters